Mohammed Saleh
Researcher / guest
- Name
- M.A.A.E.W. Saleh MSc
- Telephone
- +31 71 527 2727
- m.a.a.e.w.saleh@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-0517-6051
-
Researcher / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2023), Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?, European Journal of Pharmaceutical Sciences 187: 106482.
- Saleh M.A.A.E.W., Gülave B., Campagne O., Stewart C.F., Elassaiss J. & Lange E.C.M. de (2023), Using the LeiCNS-PK3.0 physiologically-based pharmacokinetic model to predict brain extracellular fluid pharmacokinetics in mice, Pharmaceutical Research 40: 2555-2566.
- Aulin L.B.S., Tandar S.T., Zijp T. van, Ballegooie E. van, Graaf P.H. van der, Saleh M.A.A.E.W., Välitalo P. & Hasselt J.G.C. van (2022), Physiologically based modelling framework for prediction of pulmonary pharmacokinetics of antimicrobial target site concentrations, Clinical Pharmacokinetics 61: 1735-1748.
- Hirasawa M., Saleh M.A.A.E.W. & Lange E.C.M. de (2022), The extension of the LeiCNS-PK3.0 model in combination with the “handshake” approach to understand brain tumor pathophysiology, Pharmaceutical Research : .
- Saleh M.A.A.E.W., Bloemberg J.S., Elassaiss-Schaap J. & Lange E.C.M. de (2022), Drug distribution in brain and cerebrospinal fluids in relation to IC50 values in aging and Alzheimer's disease, using the physiologically based LeiCNS-PK3.0 model, Pharmaceutical Research 39(7): 1303-1319.
- Saleh M.A.A.E.W., Hirasawa M., Sun M., Berfin G., Elassaiss J. & Lange E.C.M. de (2022), The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells, European Journal of Pharmaceutical Sciences 181: 106345.
- Saleh M.A.A.E.W., Loo C.F., Elassaiss-Schaap J. & Lange E.C.M. de (2021), Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations, Journal of Pharmacokinetics and Pharmacodynamics 48: 725-741.
- Goulooze S.C., Krekels E.H.J., Saleh M.A.A.E.W., Ahlers S.J., Valitalo P.A.J., Dongen E.P. van, Schaik R.H. van, Hankemeier T., Tibboel D. & Knibbe C.A.J. (2021), Predicting unacceptable pain in cardiac surgery patients receiving morphine maintenance and rescue doses: a model-based pharmacokinetic-pharmacodynamic analysis, Anesthesia and Analgesia 132(3): 726-734.
- Aulin L.B.S., Lange D.W. de, Saleh M.A.A., Graaf P.H. van der, Völler S. & Hasselt J.G.C. (2021), Biomarker-guided individualization of antibiotic therapy, Clinical Pharmacology & Therapeutics 110(2): 346-360.
- Saleh M.A.A.E.W. & Lange E.C.M. de (2021), Impact of CNS diseases on drug delivery to brain extracellular and intracellular target sites in human: a “WHAT-IF” Simulation Study, Pharmaceutics 13(1): 95.
- Saleh M.A.A.E.W., Garde E.M.W. van de & Hasselt J.G.C. van (2018), Host-response biomarkers for the diagnosis of bacterial respiratory tract infections, Clinical Chemistry and Laboratory Medicine 57(4): 442-451.